(Q24606177)
Statements
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib (English)
0 references
Mark G Kris
1 reference
February 2012
0 references
7
0 references
434-42
0 references
2
0 references